Introduction
============

Visual acuity (VA) outcomes after treatment of delayed-onset bleb-associated endophthalmitis (BAE) are poor.[@b1-opth-5-739]--[@b10-opth-5-739] Only 22%--67% of eyes with BAE achieve a VA outcome of 20/400 or better. The most frequent causative organisms isolated include *Streptococcus* sp. and Gram-negative organisms in 31%--57% and 15%--32% of cases, respectively.[@b1-opth-5-739]--[@b6-opth-5-739]

The association between culture results and VA outcomes has been addressed in small case series.[@b1-opth-5-739]--[@b6-opth-5-739] In one study there was no significant difference between VA outcomes of eyes with *Streptococcus* sp., non-*Streptococcus* Gram-positive organisms, and Gram-negative organisms.[@b2-opth-5-739] Another study showed no significant difference between VA outcomes of eyes with *Streptococcus* and *Staphylococcus* sp.[@b3-opth-5-739] Others reported VA outcomes for eyes with *Streptococcus* sp. and non-*Streptococcus* organisms but did not perform a comparative analysis.[@b4-opth-5-739]--[@b6-opth-5-739] The inability to identify a significant association between VA outcomes and culture result may be due to the relatively small number of reported BAE cases and the pre-existing ocular disease in these patients.

It is also unclear if the clinical presentation of BAE differs by culture result. Presently no studies have reported presenting clinical information (eg, intraocular pressure, presence of hypopyon, view of the fundus) by culture result. The purpose of the current study is to determine how culture results are associated with clinical presentations and outcomes in BAE by performing a comparative analysis within a large case series.

Methods
=======

The study protocol was approved by the Institutional Review Board of the University of Miami Miller School of Medicine Subcommittee for the Protection of Human Subjects in Research. The medical records and microbiologic records of all patients treated for BAE at Bascom Palmer Eye Institute (BPEI) between January 1, 1996 and December 31, 2009 were reviewed. All patients had prior glaucoma filtering surgery. BAE was defined as intraocular infection with vitreous involvement receiving treatment with intravitreal antibiotics. Patients with tube shunts as the filtering mechanism, bleb infection only (no posterior inflammation), onset within 1 month of glaucoma surgery, and inadvertent filtering blebs after cataract surgery were excluded. Clinical history and presentation, treatment, intraocular culture data, VA outcomes, and factors affecting VA were recorded. The current study included clinical information from the series of 71 eyes treated at BPEI between January 1, 1996 and July 1, 2008, which has been reported previously.[@b1-opth-5-739]

Snellen VAs were converted to logMAR equivalents for statistical analysis; VAs of hand motion, light perception, and no light perception were assigned logMAR values of 2.6, 3, and 4 respectively. Change in VA was determined by comparing the last recorded VA before the onset of endophthalmitis with VA at 3 months. The mean logMAR change at 3 months after presentation (3-month logMARΔ) and other clinical data were grouped by culture result and compared using the 2-sided Student's *t*-test. A *P*-value of ≤0.05 was considered statistically significant.

Results
=======

Eighty-six eyes of 85 patients were identified. Two eyes were primarily eviscerated. Intraocular culture results were positive in 53 of 84 eyes, 63% *Streptococcus* sp. and Gram-negative organisms were the most frequent isolates, accounting for 25% and 18% of cases respectively. In five eyes, two organisms were isolated. All isolated organisms were sensitive to the intravitreal antibiotics clinically administered which included Vancomycin and Ceftazidime in 77 eyes, 92%, Vancomycin and Amikacin in two eyes, Vancomycin and Gentamicin in one eye, Vancomycin alone in two eyes, Ceftazidime and Amikacin in one eye, and Cefazolin and Gentamicin in one eye. Intravitreal Dexamethasone injections were given to 69 eyes, 82%. All eyes received topical antibiotics and steroids.

A comparison of culture-positive and culture-negative cases showed no significant difference in baseline demographics ([Table 1](#t1-opth-5-739){ref-type="table"}). A greater number of culture-positive cases presented with a poor view of the fundus. The mean presenting intraocular pressure (IOP) was higher in culture-positive cases with no significant difference in final IOP. The mean pre-endophthalmitis VA showed no significant difference between groups, however mean presenting VA and 3-month logMARΔ were worse in culture-positive cases ([Figures 1](#f1-opth-5-739){ref-type="fig"} and [2](#f2-opth-5-739){ref-type="fig"}).

Comparing *Streptococcus* cases with non-*Streptococcus* Gram-positive and coagulase-negative *Staphylococcus* cases showed no significant difference in baseline demographics ([Table 2](#t2-opth-5-739){ref-type="table"}). The *Streptococcus* cases presented with a higher mean IOP and greater number of cases with a poor view of the fundus. A higher number of coagulase-negative *Staphylococcus* cases received tap and injection as the initial treatment. There was no significant difference in mean pre-endophthalmitis VA or presenting VA, however 3-month logMARΔ was significantly worse in *Streptococcus* cases ([Figure 3](#f3-opth-5-739){ref-type="fig"}).

A comparison of Gram-negative cases with coagulase-negative *Staphylococcus* cases showed that fewer Gram-negative cases achieved VA ≥20/400 at 3 months ([Table 3](#t3-opth-5-739){ref-type="table"}). *Pseudomonas* and *Serratia* cases were associated with a poor view of the fundus, higher mean presenting IOP, and a worse 3-month logMARΔ compared with coagulase-negative *Staphylococcus* cases*. Pseudomonas* and *Serratia* cases were also associated with a poor view of the fundus and worse 3-month logMARΔ compared to *Moraxella* cases ([Figure 4](#f4-opth-5-739){ref-type="fig"}).

*Streptococcus* and *Serratia* cases were associated with enucleation or evisceration ([Table 4](#t4-opth-5-739){ref-type="table"}). Six of seven eyes that received an additional treatment of enucleation or evisceration had a culture result of *Streptococcus* or *Serratia* sp.

Discussion
==========

The current study reports associations between culture results and clinical presentations and outcomes not clearly demonstrated in previous BAE series. The inability to detect these associations in past studies may have been due to the limited power inherent in smaller case series and the manner in which VA outcomes were analyzed. Previous BAE studies reported the percentage of eyes ≥20/400 or the loss of ≥5 Snellen lines.[@b1-opth-5-739]--[@b6-opth-5-739] While this information is clinically descriptive, it may be limited for comparative purposes by the poor baseline VA of many glaucomatous eyes. Mean logMARΔ more precisely measures VA outcomes in low vision eyes.

The broad groups of causative organisms used in past BAE case series may also have limited the ability to detect associations with VA outcomes. A previous BAE case series used the classification of non-*Streptococcus* Gram-positive organisms.[@b2-opth-5-739] Non-*Streptococcus* Gram-positive organisms include a wide range of organisms such as *Staphylococcus aureus*, *Enterococcus*, and coagulase-negative *Staphylococcus* cases that have varying VA outcomes. The current study narrowed the analysis to individual causative organisms, strengthening associations with VA outcomes.

An analysis of Gram-negative cases by individual organism showed that *Pseudomonas* and *Serratia* cases had worse mean VA outcomes than *Moraxella* cases. The relatively good VA outcomes of *Moraxella* cases, 71% ≥ 20/400, confirms the previous report by Berrocal et al of favorable outcomes with *Moraxella* cases.[@b11-opth-5-739]

The current study also provides insight into the clinical presentation of causative organisms in BAE. *Streptococcus, Pseudomonas*, and *Serratia* cases were associated with a higher mean IOP and worse view of the fundus than coagulase-negative *Staphylococcus* cases. Similarly culture positive cases were associated with a worse presenting VA and higher presenting IOP than culture negative cases. The clinician can consider the increased likelihood of a more virulent organism and worse visual prognosis when the patient presents with poor VA, high IOP, and poor view of the fundus.

The VA outcome analysis provided in this study confirms what clinicians have suspected for decades. Worse VA outcomes in BAE are associated with the most frequent isolates, *Streptococcus* sp. and Gram-negative organisms such as *Pseudomonas* and *Serratia* sp. When discussing prognosis, clinicians may consider that eyes with *Streptococcus* sp. and Gram-negative organisms had VA outcomes ≥ 20/400 in only 45% and 46% of cases respectively while eyes with coagulase-negative *Staphylococcus* sp. Achieved ≥20/400 in 89% of cases.

Interestingly coagulase-negative *Staphylococcus* cases achieved better VA outcomes despite less aggressive treatment. Only 11% of the coagulase-negative *Staphylococcus* cases received pars plana vitrectomy compared with 57% of the *Streptococcus* cases. The higher mean IOP and worse view of the fundus in the *Streptococcus* cases likely compelled the treating clinician to more frequently favor pars plana vitrectomy. The role pars plana vitrectomy plays in BAE can only be determined by a sufficiently powered prospective randomized control trial. Unfortunately this may not be feasible due to the limited number of BAE cases.

The current study was not designed to determine the best management for BAE, but it does provide insight into the key role causative organisms play in the clinical presentation and prognosis of BAE. Culture-positive cases were associated with worse presenting VA, higher presenting IOP, and worse VA outcomes than culture-negative cases. *Streptococcus*, *Pseudomonas,* and *Serratia* cases were associated with poor presenting view of the fundus and worse VA outcomes than coagulase-negative *Staphylococcus* and *Moraxella* cases.
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![Photograph of right eye of 66-year-old male presenting with BAE from *Streptococcus* sp. Presenting VA: HM, IOP: 28 mmHg. Treatment: tap and injection. Final VA: HM, IOP: 12 mmHg. Culture-positive cases were associated with worse presenting VA and higher presenting IOP than culture-negative cases.\
**Abbreviations:** BAE, bleb-associated endophthalmitis; HM, hand motion; IOP, intraocular pressure; VA, visual acuity.](opth-5-739f1){#f1-opth-5-739}

![Photograph of left eye of 67-year-old male presenting with culture-negative BAE. Presenting VA: 20/200, IOP: 10 mmHg. Treatment: tap and injection. Final VA 20/200, IOP 16 mmHg. Culture-negative cases were associated with better VA outcomes than culture-positive cases.\
**Abbreviations:** BAE, bleb-associated endophthalmitis; IOP, intraocular pressure; VA, visual acuity.](opth-5-739f2){#f2-opth-5-739}

![Photograph of left eye of 79-year-old female presenting with BAE from *Streptococcus* sp. Presenting VA: LP, IOP: 40 mmHg. Treatment: pars plana vitrectomy. Final VA: LP, IOP: 0 mmHg. Only 45% of *Streptococcus* cases had VA outcomes ≥ 20/400.\
**Abbreviations:** BAE, bleb-associated endophthalmitis; IOP, intraocular pressure; LP, light perception; VA, visual acuity.](opth-5-739f3){#f3-opth-5-739}

![Photograph of left eye of 72-year-old female with BAE from *Moraxella* sp. Presenting VA: 1/200, IOP: 35 mmHg. Treatment: tap and injection. Final VA: 20/25, IOP: 11 mmHg. *Moraxella* cases were associated with a better presenting view of the fundus and better VA outcomes than *Pseudomonas* and *Serratia* cases.\
**Abbreviations:** BAE, bleb-associated endophthalmitis; IOP, intraocular pressure; VA, visual acuity.](opth-5-739f4){#f4-opth-5-739}

###### 

Culture-positive and culture-negative cases

                                              **Culture-positive**   **Culture-negative**
  ------------------------------------------- ---------------------- ----------------------------------------------------
  Age                                                                
    Mean, SD                                  75 (12)                71 (13)
  Gender                                                             
    Female                                    26 (50%)               15 (48%)
    Male                                      26 (50%)               16 (52%)
  Diabetes mellitus                                                  
    Present                                   6 (12%)                5 (17%)
    Absent                                    46 (88%)               25 (83%)
  Antimetabolites                                                    
    Used                                      33 (64%)               20 (69%)
    Not used                                  19 (36%)               9 (31%)
  Bleb leak                                                          
    Present                                   10 (19%)               11 (35%)
    Absent                                    43 (81%)               20 (65%)
  Mean time of onset of endophthalmitis, SD   64 months (46)         49 months (42)
  Anterior chamber                                                   
  Hypopyon                                    36 (68%)               23 (74%)
  View to fundus                                                     
    Hazy                                      15 (28%)               15 (48%)
    Poor/none                                 38 (72%)               16 (52%)
  Intraocular pressure                                               
    Presentation, SD                          24 (15)                14 (9)[\*](#tfn2-opth-5-739){ref-type="table-fn"}
  Treatment, initial                                                 
    Tap and injection                         30 (57%)               24 (77%)
    Pars plana vitrectomy                     23 (43%)               7 (23%)
  Treatment, additional                                              
    Filtering procedure                       7 (13%)                6 (19%)
    Pars plana vitrectomy                     19 (36%)               5 (16%)[\*](#tfn2-opth-5-739){ref-type="table-fn"}
  VA before endophthalmitis                   n = 50                 n = 31
    Mean                                      20/81                  20/95
    Range                                     20/20-LP               20/25-CF
  Presenting VA                               n = 53                 n = 31
    Mean                                      0.7/200                1.6/200[\*](#tfn2-opth-5-739){ref-type="table-fn"}
    Range                                     20/40-NLP              20/50-LP
  VA 3 months posttreatment                   n = 47                 n = 19
    Mean                                      4.1/200                20/209[\*](#tfn2-opth-5-739){ref-type="table-fn"}
    Range                                     20/25-NLP              20/25-LP
    20/400 or better                          26 (55%)               14 (74%)
  LogMARΔ                                     1.03                   0.43[\*](#tfn2-opth-5-739){ref-type="table-fn"}

**Note:**

*P* ≤ 0.05, culture-positive compared to culture-negative cases.

**Abbreviations:** CF, counting fingers; LP, light perception; NLP, no light perception; SD, standard deviation; VA, visual acuity.

###### 

Gram-positive cases

                                              ***Streptococcus***   **Non-*Streptococcus*Gram-positive**                  **Coagulase-negative*Staphylococcus***                ***Enterococcus***
  ------------------------------------------- --------------------- ----------------------------------------------------- ----------------------------------------------------- --------------------
  Age                                                                                                                                                                           
    Mean, SD                                  72 (14)               77 (8)                                                77 (9)                                                76 (9)
  Gender                                                                                                                                                                        
    Female                                    9 (45%)               7 (41%)                                               3 (33%)                                               3 (50%)
    Male                                      11 (55%)              10 (59%)                                              6 (67%)                                               3 (50%)
  Diabetes mellitus                                                                                                                                                             
    Present                                   2 (10%)               1 (6%)                                                1 (11%)                                               0 (0%)
    Absent                                    18 (90%)              16 (94%)                                              8 (89%)                                               6 (100%)
  Antimetabolites                                                                                                                                                               
    Used                                      11 (55%)              14 (82%)                                              9 (100%)                                              3 (50%)
    Not used                                  9 (45%)               3 (18%)                                               0 (0%)                                                3 (50%)
  Bleb leak                                                                                                                                                                     
    Present                                   4 (19%)               4 (24%)                                               3 (33%)                                               1 (17%)
    Absent                                    17 (81%)              13 (76%)                                              6 (67%)                                               4 (67%)
  Anterior chamber                                                                                                                                                              
    Hypopyon                                  11 (52%)              13 (77%)                                              7 (78%)                                               4 (67%)
  View to fundus                                                                                                                                                                
    Hazy                                      2 (10%)               9 (53%)                                               5 (56%)                                               2 (33%)
    Poor/none                                 19 (90%)              8 (47%)[\*](#tfn5-opth-5-739){ref-type="table-fn"}    4 (44%)[^†^](#tfn6-opth-5-739){ref-type="table-fn"}   4 (67%)
  Mean time of onset of endophthalmitis, SD   71 months (40)        64 months (57)                                        57 months (58)                                        77 months (72)
  Intraocular pressure                                                                                                                                                          
    Presentation, SD                          29 (16)               18 (15)[\*](#tfn5-opth-5-739){ref-type="table-fn"}    11 (8)[^†^](#tfn6-opth-5-739){ref-type="table-fn"}    30 (17)
  Treatment, initial                                                                                                                                                            
    Tap and injection                         9 (43%)               12 (71%)                                              8 (89%)[^†^](#tfn6-opth-5-739){ref-type="table-fn"}   3 (50%)
    Pars plana vitrectomy                     12 (57%)              5 (29%)                                               1 (11%)                                               3 (50%)
  Treatment, additional                                                                                                                                                         
    Filtering procedure                       2 (10%)               5 (29%)                                               4 (44%)[^†^](#tfn6-opth-5-739){ref-type="table-fn"}   0 (0%)
    Pars plana vitrectomy                     10 (48%)              3 (18%)[\*](#tfn5-opth-5-739){ref-type="table-fn"}    1 (11%)[^†^](#tfn6-opth-5-739){ref-type="table-fn"}   2 (33%)
  VA before endophthalmitis                   n = 19                n = 17                                                n = 9                                                 n = 6
    Mean                                      20/62                 20/73                                                 20/54                                                 20/167
    Range                                     20/20-4/200           20/20-LP                                              20/25-20/200                                          20/25-LP
  Presenting VA                               n = 21                n = 17                                                n = 9                                                 n = 6
    Mean                                      0.5/200               0.8/200                                               1/200                                                 0.5/200
    Range                                     20/40-LP              20/80-NLP                                             20/200-LP                                             20/80-NLP
  VA 3 months posttreatment                   n = 20                n = 14                                                n = 9                                                 n = 4
    Mean                                      1.9/200               20/209[\*](#tfn5-opth-5-739){ref-type="table-fn"}     20/110[^†^](#tfn6-opth-5-739){ref-type="table-fn"}    3/200
    Range                                     20/30-NLP             20/25-LP                                              20/25-HM                                              20/100-LP
    20/400 or better                          9 (45%)               11 (79%)[\*](#tfn5-opth-5-739){ref-type="table-fn"}   8 (89%)[^†^](#tfn6-opth-5-739){ref-type="table-fn"}   2 (50%)
  LogMARΔ                                     1.44                  0.46[\*](#tfn5-opth-5-739){ref-type="table-fn"}       0.31[^†^](#tfn6-opth-5-739){ref-type="table-fn"}      0.89

**Notes:**

*P* ≤ 0.05, *Streptococcus* compared to non-*Streptococcus* Gram-positive cases;

*P* ≤ 0.05, *Streptococcus* compared to coagulase-negative *Staphylococcus* cases.

**Abbreviations:** HM, hand motion; LP, light perception; NLP, no light perception; SD, standard deviation; VA, visual acuity.

###### 

Gram-negative cases

                                              **Gram-negative**                                    ***Moraxella***                                        ***Pseudomonas***   ***Serratia***
  ------------------------------------------- ---------------------------------------------------- ------------------------------------------------------ ------------------- -------------------------------------------------------
  Age                                                                                                                                                                         
    Mean, SD                                  78 (14)                                              72 (11)                                                82 (18)             89 (12)
  Gender                                                                                                                                                                      
    Female                                    10 (67%)                                             4 (50%)                                                3 (100%)            2 (67%)
    Male                                      5 (33%)                                              4 (50%)                                                0 (0%)              1 (33%)
  Diabetes mellitus                                                                                                                                                           
    Present                                   3 (20%)                                              2 (25%)                                                1 (33%)             0 (0%)
    Absent                                    12 (80%)                                             6 (75%)                                                2 (67%)             3 (100%)
  Antimetabolites                                                                                                                                                             
    Used                                      8 (53%)                                              5 (63%)                                                1 (33%)             2 (67%)
    Not used                                  7 (47%)                                              3 (37%)                                                2 (67%)             1 (33%)
  Bleb leak                                                                                                                                                                   
    Present                                   2 (13%)                                              2 (75%)                                                0 (0%)              0 (0%)
    Absent                                    13 (87%)                                             6 (75%)                                                3 (100%)            3 (100%)
  Anterior chamber                                                                                                                                                            
  Hypopyon                                    12 (80%)                                             6 (75%)                                                2 (67%)             3 (100%)
  View to fundus                                                                                                                                                              
    Hazy                                      4 (27%)                                              4 (50%)                                                0 (0%)              0 (0%)
    Poor/none                                 11 (73%)                                             4 (50%)[^†^](#tfn10-opth-5-739){ref-type="table-fn"}   3 (100%)            3 (100%)[^‡^](#tfn11-opth-5-739){ref-type="table-fn"}
  Mean time of onset of endophthalmitis, SD   51 months (36)                                       56 months (32)                                         57 months (77)      34 months (38)
  Intraocular pressure                                                                                                                                                        
    Presentation, SD                          22 (12)[\*](#tfn9-opth-5-739){ref-type="table-fn"}   23 (15)                                                26 (12)             18 (4)[^‡^](#tfn11-opth-5-739){ref-type="table-fn"}
  Treatment, initial                                                                                                                                                          
    Tap and injection                         9 (60%)                                              5 (63%)                                                1 (33%)             2 (67%)
    Pars plana vitrectomy                     6 (40%)                                              3 (37%)                                                2 (67%)             1 (33%)
  Treatment, additional                                                                                                                                                       
    Filtering procedure                       0 (0%)                                               0 (0%)                                                 0 (0%)              0 (0%)
    Pars plana vitrectomy                     6 (40%)[\*](#tfn9-opth-5-739){ref-type="table-fn"}   4 (50%)[^†^](#tfn10-opth-5-739){ref-type="table-fn"}   0 (0%)              1 (33%)
  VA before endophthalmitis                   n = 14                                               n = 7                                                  n = 3               n = 3
    Mean                                      20/131                                               20/194                                                 20/141              20/74
    Range                                     20/25-HM                                             20/25-HM                                               20/40-4/200         20/50-20/100
  Presenting VA                               n = 15                                               n = 8                                                  n = 3               n = 3
    Mean                                      0.9/200                                              1.4/200                                                1.6/200             LP
    Range                                     20/80-LP                                             20/80-LP                                               20/100-LP           HM-LP
  VA 3 months posttreatment                   n = 13                                               n = 7                                                  n = 2               n = 3
    Mean                                      2.5/200[\*](#tfn9-opth-5-739){ref-type="table-fn"}   20/264[^†^](#tfn10-opth-5-739){ref-type="table-fn"}    LP                  LP[^‡^](#tfn11-opth-5-739){ref-type="table-fn"}
    Range                                     20/40-NLP                                            20/40-HM                                               LP-LP               LP-NLP
    20/400 or better                          6 (46%)[\*](#tfn9-opth-5-739){ref-type="table-fn"}   5 (71%)[^†^](#tfn10-opth-5-739){ref-type="table-fn"}   0 (0%)              0 (0%)[^‡^](#tfn11-opth-5-739){ref-type="table-fn"}
  LogMARΔ                                     1.08                                                 0.04[^†^](#tfn10-opth-5-739){ref-type="table-fn"}      1.88                2.77[^‡^](#tfn11-opth-5-739){ref-type="table-fn"}

**Note:**

*P* ≤ 0.05, Gram-negative compared to coagulase-negative *Staphylococcus* cases.

*P ≤* 0.05, *Pseudomonas* and *Serratia* compared to *Moraxella* cases.

*P ≤* 0.05, *Pseudomonas* and *Serratia* compared to coagulase-negative *Staphylococcus* cases.

**Abbreviations:** HM, hand motion; LP, light perception; NLP, no light perception; SD, standard deviation; VA, visual acuity.

###### 

Enucleation or evisceration in nine eyes (10%)

  **Case \#**   **Culture result**               **Initial treatment**   **Additional treatment**
  ------------- -------------------------------- ----------------------- --------------------------
  5             *Serratia* and *Streptococcus*   T&I                     Enucleation
  17            *Serratia*                       T&I                     Enucleation
  33            *Serratia*                       PPV                     Evisceration
  26            *Streptococcus*                  T&I                     Evisceration
  37            *Streptococcus*                  PPV                     Enucleation
  43            *Streptococcus*                  PPV                     Enucleation
  46            No growth                        PPV                     Evisceration
  25            Not done                         Evisceration            
  70            Not done                         Evisceration            

**Note:** *P* = 0.01, Enucleation or evisceration for *Streptococcus* or *Serratia* compared with other culture results.

**Abbreviations:** PPV, Pars planavitrectomy; T&I, tap and injection.
